Trillium Therapeutics (TRIL) Upgraded to Hold by ValuEngine

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Friday.

A number of other research firms have also issued reports on TRIL. Zacks Investment Research lowered shares of Trillium Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 1st. HC Wainwright set a $7.00 price target on shares of Trillium Therapeutics and gave the company a “buy” rating in a report on Monday, August 14th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $12.33.

Shares of Trillium Therapeutics (NASDAQ:TRIL) opened at $11.05 on Friday. Trillium Therapeutics has a 1-year low of $4.15 and a 1-year high of $13.30. The company has a current ratio of 6.33, a quick ratio of 6.33 and a debt-to-equity ratio of 0.01.

Hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC bought a new stake in Trillium Therapeutics in the second quarter worth approximately $2,395,000. Victory Capital Management Inc. grew its position in Trillium Therapeutics by 88.9% in the second quarter. Victory Capital Management Inc. now owns 146,571 shares of the biotechnology company’s stock worth $645,000 after acquiring an additional 68,970 shares in the last quarter. K2 Principal Fund L.P. bought a new stake in Trillium Therapeutics in the second quarter worth approximately $264,000. AWM Investment Company Inc. bought a new stake in Trillium Therapeutics in the second quarter worth approximately $4,415,000. Finally, Sectoral Asset Management Inc grew its position in Trillium Therapeutics by 42.9% in the second quarter. Sectoral Asset Management Inc now owns 183,272 shares of the biotechnology company’s stock worth $806,000 after acquiring an additional 55,000 shares in the last quarter. 47.45% of the stock is owned by institutional investors.

WARNING: “Trillium Therapeutics (TRIL) Upgraded to Hold by ValuEngine” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/02/trillium-therapeutics-tril-upgraded-to-hold-by-valuengine.html.

About Trillium Therapeutics

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply